Scarica l'app Stockscreener
101.24
3.33%
3.26
Dopo l'orario di chiusura:
100.88
-0.36
-0.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo Finance
Mirum and Incyte to present FOP drug trial results at ENDO 2026 - Investing.com
Mirum and Incyte to present zilurgisertib study results at ENDO 2026 - StreetInsider
Zilurgisertib FOP data to debut at ENDO 2026 before Sept. 26 FDA PDUFA date - Stock Titan
Incyte Corp. stock outperforms competitors on strong trading day - MSN
Incyte shares rise 6.2% amid renewed optimism around late-stage pipeline and recent partnership update - Quiver Quantitative
Incyte Stock Drops as Cancer Drug Data Hits: Wall Street Split Remains in Focus - Bez Kabli
Citizens maintains Incyte stock rating on pipeline progress By Investing.com - Investing.com Australia
Citizens maintains Incyte stock rating on pipeline progress - Investing.com
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Stifel reiterates Incyte stock Buy rating on DLBCL data strength - Investing.com
H.C. Wainwright reiterates Incyte stock rating on lymphoma data - Investing.com
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL - BioSpace
Incyte (INCY) Reports Positive Phase 3 Trial Results for Tafasit - GuruFocus
Incyte (INCY) Reports Positive Phase 3 Trial Results for Tafasitamab - GuruFocus
Incyte (INCY) Monjuvi Shows Promise as First-Line Treatment for Lymphoma - GuruFocus
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate By Reuters - Investing.com
Incyte drug combo cuts risk of high-risk lymphoma worsening by 25% - Stock Titan
INCY News | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte (INCY) accounting officer sells 2,051 common shares - Stock Titan
INCYTE (NASDAQ: INCY) director exercises 15,000 options and has shares withheld for taxes - Stock Titan
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report? - Yahoo Finance
Morgan Stanley sells INCY common shares (INCY) via Form 144 notice - Stock Titan
DIADEMA PARTNERS LP's Incyte Corp(INCY) Holding History - GuruFocus
Here's Why Incyte (INCY) is a Strong Momentum Stock - Yahoo Finance
Incyte to stream Goldman Sachs healthcare conference talk June 9 - Stock Titan
1INCY.MI Stock Price, Quote & Chart | INCYTE CORP (BIT:1INCY) - ChartMill
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out - Barchart.com
INCYTE CORP (NASDAQ:INCY) Shows Rare Alignment of High Growth Momentum and Technical Breakout Setup - ChartMill
Continuum Advisory, LLC's Incyte Corp(INCY) Holding History - GuruFocus
INCY Initiates Coverage On Bernstein -- Rating Set to Market Per - GuruFocus
Here's Why Incyte (INCY) is a Strong Value Stock - Yahoo Finance
How Incyte’s AI-Powered R&D Partnerships At Incyte (INCY) Has Changed Its Investment Story - Yahoo Finance
Bernstein initiates Incyte stock coverage with concerns on growth By Investing.com - Investing.com South Africa
Incyte (INCY) Coverage Initiated with Caution by Bernstein - GuruFocus
Bernstein initiates Incyte stock coverage with concerns on growth - Investing.com UK
Bernstein SocGen Group Starts Incyte (INCY) at Market Perform - StreetInsider
2.89%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):